Professional Documents
Culture Documents
Adhd
Adhd
WINTER
Template
Epidemiology
02
WINTER
Epidemiology
03
WINTER
Epidemiology
05
WINTER
Template
Epidemiology
06
WINTER
Epidemiology
08
WINTER
Epidemiology
10
WINTER
The 1st study showed that the new rating scale for
ADHD was valid. The 2nd study revealed that the
prevalence
Fayoum
City was
20.5%,
with
The Prevalenceof
of ADHD
ADHD in in
Fayoum
City (Egypt)
Among
School33.8%
among
boys and
among girls.
Age
Children:
Depending
on a6.8%
DSM-5-Based
Rating Scale.
Aboul-Ata MA, Amin FA. J Atten Disord. 2015.
Epidemiology
11
WINTER
Epidemiology
12
WINTER
Epidemiology
13
WINTER
Epidemiology
14
WINTER
Epidemiology
15
WINTER
Epidemiology
16
WINTER
Afify MF, Yehia MA, Abdel-Naem EA, Abd Alkarim SM. 2010.
Epidemiology
17
WINTER
Template
There were significant differences regarding:
social state,
scholastic achievement,
first birth order,
large family size,
bottle feeding,
higher abnormal EEG findings and Hb%
between cases and control children.
Epidemiology
18
WINTER
Epidemiology
19
WINTER
Epidemiology
20
WINTER
Epidemiology
21
WINTER
Etiology
24
Etiology
25
Etiology
26
Environmental risk factors by gender associated with attentiondeficit/hyperactivity disorder. Silva D1, Colvin L, Hagemann E,
Bower C. Pediatrics. 2014.
Etiology
27
Etiology
28
Etiology
30
Etiology
31
Etiology
32
Impact
34
Impact
35
Impact
36
Impact
37
FAMILY
Frequently, difficulties at home or on outings with
carers (for example, when shopping, out in the park,
or visiting other family members) also become more
apparent at preschool age.
Parents may find that:
family members refuse to care for the child,
other children do not invite them to parties or out to
play.
Impact
38
FAMILY
Many children with ADHD have very poor sleep
patterns, and although they appear not to need much
sleep, daytime behavior is often worse when sleep is
badly affected.
As a result, parents have little time to themselves;
whenever the child is awake they have to be watching
them.
Not surprisingly, family relationships may be severely
strained, and in some cases break down, bringing
additional social and financial difficulties. This may
cause children to feel sad or even show oppositional
or aggressive behavior.
Impact
39
ADULT LIFE
As many as 60% of individuals with ADHD in
childhood continue to have difficulties in adult life.
Childhood ADHD does not preclude high
educational and vocational achievements (for
example, Masters degree or medical qualification).
However, ADHD is a disorder that may affect all
aspects of a childs life.
COMORBIDITIES
Comorbid disorders may impact on individuals with
ADHD throughout their lives. It is estimated that at
least 65% of children with ADHD have 1 or more
The effect of ADHD on the life of an individual, their family, and
comorbid conditions.
community from preschool to adult life. V Harpin. rch Dis Child. 2005.
Impact
40
Impact
41
HEALTHCARE COSTS
In the UK have not been fully estimated, but evidence
from the USA suggests that they are increased
compared with age matched controls.
A population based, historical cohort study followed
4880 individuals from 1987 to 1995 and compared the
nine year median medical cost per person:
ADHD medical costs were US$4306, whereas nonADHD medical costs were US$1944.
Prevention: Primary
44
Prevention: Primary
45
Prevention: Primary
46
Prevention: Secondary 47
Summary of key action statements (quality of evidence
B/strong recommendation unless stated otherwise):
The primary care clinician should:
1- Initiate an evaluation for any child 4 through 18
years of age who presents with academic or
behavioral problems and symptoms of inattention,
hyperactivity, or impulsivity.
ADHD Clinical Practice Guideline for the Diagnosis, Evaluation, and
Treatment of Attention-Deficit Hyperactivity Disorder in Children and
Adolescents. American Academy of Pediatrics AAP clinical recommen
dations for the diagnosis and evaluation of ADHD in children.
Pediatrics2011.
Prevention: Secondary 48
The primary care clinician should:
2- Determine that DSM criteria were met to make a
diagnosis & rule out any alternative cause (including
documentation of impairment in more than 1 major
setting); information should be obtained primarily from
reports from parents or guardians, teachers, and other
school and mental health clinicians involved in the
child's care.
ADHD Clinical Practice Guideline for the Diagnosis, Evaluation, and
Treatment of Attention-Deficit Hyperactivity Disorder in Children and
Adolescents. American Academy of Pediatrics AAP clinical recommen
dations for the diagnosis and evaluation of ADHD in children.
Pediatrics2011.
Prevention: Secondary 49
The primary care clinician should:
3- Include assessment for other conditions that might
coexist with ADHD in the evaluation, including
emotional or behavioral (e.g., anxiety, depressive,
oppositional defiant, and conduct disorders),
developmental (e.g., learning and language disorders
or other neurodevelopmental disorders), and physical
(eg, tics, sleep apnea) conditions.
ADHD Clinical Practice Guideline for the Diagnosis, Evaluation, and
Treatment of Attention-Deficit Hyperactivity Disorder in Children and
Adolescents. American Academy of Pediatrics AAP clinical recommen
dations for the diagnosis and evaluation of ADHD in children.
Pediatrics2011.
Prevention: Secondary 50
The primary care clinician should:
4- Recognize ADHD as a chronic condition and,
therefore, consider patients as with special health care
needs. Management of children and youth with special
health care needs should follow the principles of the
chronic care model and the medical home.
ADHD Clinical Practice Guideline for the Diagnosis, Evaluation, and
Treatment of Attention-Deficit Hyperactivity Disorder in Children and
Adolescents. American Academy of Pediatrics AAP clinical recommen
dations for the diagnosis and evaluation of ADHD in children.
Pediatrics2011.
Prevention: Secondary 51
The primary care clinician should:
5- Treat children and youth with ADHD depending on patient's age:
a. For preschool-aged children (4-5 years of age): prescribe
evidence-based parent- and/or teacher-administered behavior
therapy as the 1st line of treatment (quality of evidence A/strong
recommendation) and may prescribe Methylphenidate if the
behavior interventions do not provide significant improvement and
there is moderate-to-severe continuing disturbance in the child's
function. In areas where evidence-based behavioral treatments are
not available, the clinician needs to weigh the risks of starting
medication at an early age against the harm of delaying diagnosis
and treatment.
ADHD Clinical Practice Guideline for the Diagnosis, Evaluation, and
Treatment of Attention-Deficit Hyperactivity Disorder in Children and
Adolescents. American Academy of Pediatrics AAP clinical recommen
dations for the diagnosis and evaluation of ADHD in children.
Pediatrics2011.
Prevention: Secondary 52
The primary care clinician should:
5- Treat children and youth with ADHD depending on patient's age:
b. For elementary school-aged children (6-11 years of age),
prescribe FDA-approved medications (quality of evidence A/strong
recommendation) and/or evidence-based parent- and/or teacheradministered behavior therapy as treatment for ADHD, preferably
both. The evidence is particularly strong for stimulant medications
and sufficient but less strong for Atomoxetine, extended-release
Guanfacine, and extended-release Clonidine (in that order) (quality
of evidence A/strong recommendation). The school environment,
program, or placement is a part of any treatment plan.
ADHD Clinical Practice Guideline for the Diagnosis, Evaluation, and
Treatment of Attention-Deficit Hyperactivity Disorder in Children and
Adolescents. American Academy of Pediatrics AAP clinical recommen
dations for the diagnosis and evaluation of ADHD in children.
Pediatrics2011.
Prevention: Secondary 53
The primary care clinician should:
5- Treat children and youth with ADHD depending on patient's age:
c. For adolescents (12-18years of age), prescribe FDA -approved
medications with the assent of the adolescent (quality of evidence
A/strong recommendation) and prescribe behavior therapy as
treatment (quality of evidence C/recommendation), preferably both.
6- Titrate doses of medication for ADHD to achieve maximum
benefit with minimum adverse effects.
ADHD Clinical Practice Guideline for the Diagnosis, Evaluation, and
Treatment of Attention-Deficit Hyperactivity Disorder in Children and
Adolescents. American Academy of Pediatrics AAP clinical recommen
dations for the diagnosis and evaluation of ADHD in children.
Pediatrics2011.
Prevention: Secondary 54
44 of the 2,904 non-duplicate screened records were included in
the analyses. When the outcome measure was based on ADHD
assessments by raters closest to the therapeutic setting, all
dietary (SMD=0.21-0.48) and psychological (SMD=0.40-0.64)
treatments produced statistically significant effects. However,
when the best probably blinded assessment was employed,
effects remained significant for free fatty acid supplementation
(SMD=0.16) and artificial food color exclusion (SMD=0.42) but
were substantially attenuated to non-significant levels for other
treatments.
Nonpharmacological interventions for ADHD: systematic review and
meta-analyses of randomized controlled trials of dietary and
psychological treatments. Sonuga-Barke EJ1, Brandeis D, Cortese S,
Daley D, Ferrin M, Holtmann M, Stevenson J, Danckaerts M, van der
Oord S, Dpfner M, Dittmann RW, Simonoff E, Zuddas A, Banaschewski
T, Buitelaar J, Coghill D, Hollis C, Konofal E, Lecendreux M, Wong IC,
Sergeant J; European ADHD Guidelines Group. Am J Psychiatry. 2013.
Prevention: Secondary 55
Free fatty acid supplementation produced small but significant
reductions in ADHD symptoms even with probably blinded
assessments, although the clinical significance of these effects
remains to be determined. Artificial food color exclusion
produced larger effects but often in individuals selected for food
sensitivities. Better evidence for efficacy from blinded
assessments is required for behavioral interventions,
neurofeedback, cognitive training, and restricted elimination diets
before they can be supported as treatments for core ADHD
symptoms.
Nonpharmacological interventions for ADHD: systematic review and
meta-analyses of randomized controlled trials of dietary and
psychological treatments. Sonuga-Barke EJ1, Brandeis D, Cortese S,
Daley D, Ferrin M, Holtmann M, Stevenson J, Danckaerts M, van der
Oord S, Dpfner M, Dittmann RW, Simonoff E, Zuddas A, Banaschewski
T, Buitelaar J, Coghill D, Hollis C, Konofal E, Lecendreux M, Wong IC,
Sergeant J; European ADHD Guidelines Group. Am J Psychiatry. 2013.
Prevention: Tertiary
57
Prognosis
58
Prognosis
59
Prognosis
60
Prognosis
61
Prognosis
62
Prognosis
60
Prognosis
60
Prognosis
69
Prognosis
70
Prognosis
71
05